Table 1 Patient’s characteristics of study population
From: Detection of endocrine disorders in young children with multi-transfused thalassemia major
Characteristics | Summary statistics Total 120 patients | |
|---|---|---|
Male 66 (55%) | Female 54 (45%) | |
Age / years | ||
 Mean (SD) | 11.34 (2.27) | 11.12 (2.01) |
 Median (range) | 11.4 (2–12) | 11.6 (2–12) |
Duration of disease/years | ||
 Mean (SD) | 5.74 (3.45) | 5.14 (3.20) |
 Weight (Kg) Mean (SD) | 28 (7.65) | 25 (6.67) |
 Height (Cm) Mean (SD) | 129 (19.54) | 124 (18.35) |
Body mass index (BMI) kg/m2 | ||
 Mean (SD) | 16.82 (8.73) | 16.26 (6.78) |
 Median (range) | 16.5 (14–28) | 16.9 (15–29) |
 Malnutrition according to Z score for BMI (percentage) | 44 (66.67%) | 40 (74.07%) |
Family history of thalassemia major | ||
 No | 26 (39.39%) | 20 (37.04%) |
 Yes | 40 (60.61%) | 34 (62.96%) |
Family history of endocrine disorders | ||
 No | 41 (62.12%) | 32 (59.26%) |
 Yes | 25 (37.88%) | 22 (40.74%) |
Ferritin level | ||
 Mean (SD) | 3121 (1390) | 2997 (1480) |
 Median (range) | 2653 (58–6550) | 2342 (47–6520) |
Hemoglobin level before transfusion (Gram/DL) | ||
 Mean (SD) | 6.82 (1.45) | 6.65 (1.89) |
 Median (range) | 7.5 (2.8–11) | 7.2 (2.5–11) |
Splenectomy | ||
 No | 30 (45.45%) | 35 (64.81%) |
 Yes | 36(54.55%) | 19 (35.19%) |
Deferasirox (N. of patients) | 20 (30.30%) | 16 (29.63%) |
Desferoxamine (N. of patients) | 14 (21.22%) | 11 (20.37%) |
Combined therapy (N. of patients) | 32 (48.48%) | 27 (50%) |